MAIA Biotechnology, Inc.

Day range

$1.12 – $1.15

Open

$1.15

Prev close

$1.15

Volume

125.95K

Market cap

$71M

Shares out

61.74M

P/E

—

P/S

—

P/B

3.43

P/FCF

—

ROE

-129.8%

ROA

-95.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Business updateOct 6, 2026

  The Company has prepared a summary ("Summary") highlighting certain aspects of the operations and performance that management intends to use in presentations on or after October 6, 2026, which Summary was posted to the Company's website on October 6, 2026. The Summary is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

• Annual meeting resultsMay 22, 2026

  On May 21, 2026, MAIA Biotechnology, Inc. held its 2026 Annual Meeting of stockholders. Stockholders re-elected both of the Company's Class I nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2029. Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Deal terminationMay 14, 2026

  On May 14, 2026, MAIA Biotechnology, Inc. (the "Company") suspended sales of its common stock, par value $0.0001 per share ("Common Stock"), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the "Agent"), the Company's sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination will be effective 7-business days after May 14, 2026, in accordance with the terms of the sales agreement.

• Capital allocation updateApr 8, 2026

  MAIA Biotechnology, Inc. issued a press release entitled 'MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy' on April 8, 2026.

• Executive compensation changeApr 2, 2026

  On March 27, 2026, the Board of Directors of MAIA Biotechnology, Inc. (the "Company") approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company's Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company's Head of Finance, in consideration for their efforts in connection with the Company's recent capital raise.

Days to cover

3.4

Short interest

2.69M

Avg volume

784.61K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
  positiveGlobeNewswire Inc.· Mar 5, 2026
• MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Mar 4, 2026
• MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Mar 2, 2026
• MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
  positiveGlobeNewswire Inc.· Mar 2, 2026
• $207B Market Shift: The Race for Fast Track Approval in Oncology
  positiveBenzinga· Feb 5, 2026